Press Releases

Biopharma PEG Supplies High Quality Cholesterol (Plant-Derived)

About us Biopharma PEG Scientific Inc. is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity monodispersed and polydispersed polyethylene glycol (PEG) derivatives and PEG raw material, PEGylation services, and custom PEG derivative synthesis to clients worldwide. We continuously expand the capability to provide large-scale manufacture of high purity PEG derivatives with an extensive variety of functional groups, in both non-GMP and GMP grade. Contact us Biopharma PEG Scientific Inc. Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA TEL: 1-857-366-6766 Fax: 617-206-9595 Email: sales@biochempeg.com Website:https://www.biochempeg.com/

HONEYWELL AND RECIPHARM TO SPEED DEVELOPMENT OF INHALERS WITH A NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT

Partnership to reduce environmental footprint of inhalers

Evoke launches audience intelligence offering to unlock the full commercial potential of life sciences brands

Leading global health and life science brand Evoke has launched a major new audience intelligence service offering to benefit their roster of international pharma and life science clients.

Hyfe AI and ActiGraph Partner to Revolutionize Clinical Trials with AI-Powered Cough Detection

Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.

Amerigo Scientific Introduces Water Purification Systems for Life Science Research

CD Computabio Unleashes the Power of Computational Biology with Innovative Virtual Screening Service

NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

Exothera S.A. has announced that the National Institutes of Health, the US’s medical research agency, has selected them to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy

SSI Strategy has announced that it has entered into a definitive agreement to acquire NDA Group AB. This strategic combination will create a premier consultancy, specializing in guiding drug development companies from concept to commercialization.

Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies

Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies Accelerating Biotech Success

X-Chem Appoints Chief Scientific Officer and Chief Financial Officer

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, announced the addition of Karen Lackey as chief scientific officer (CSO) and David Hagerman as chief financial officer (CFO) to its global executive management team.

Phastar Appoints Graham Clark as New Chief Executive Officer

Phastar Appoints Graham Clark as New Chief Executive Officer Phastar Sets Course for Further Growth with New CEO Appointment

ICS/ICB leaders Penny Dash and Paul Miller announced as speakers for the NHS Transformation Symposium

Mtech Access has announced that its annual NHS Transformation Symposium, this September, will feature guest speakers Penny Dash and Paul Miller, who hold strategic leadership roles in an Integrated Care Systemand Board, respectively.

RBQMLive, Sponsored by CluePoints, Wins Prestigious Sales and Marketing Award

RBQMLive, Sponsored by CluePoints, Wins Prestigious Sales and Marketing Award Two-day educational conference tops the experiential/event marketing category at the Sales and Marketing Technology Awards 2023

Huateng Pharma Develops CAS NO.156-83-2 (Minoxidil Intermediate) Against Hair Loss

About Huateng Pharma Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility. Contact us Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818

iotaSciences appoints Dr. Michael Lutz as new Chief Executive Officer

iotaSciences has announced today the appointment of Dr. Michael Lutz as CEO and Director for Iota Sciences Ltd.

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Kiora Pharmaceuticals of Encinitas announced a sharpened focus on its KIO-310 vision-restoring treatments for retinal diseases. This is based largely on preliminary results observed in a recent ABACUS Phase 1b clinical trial that indicates the possibility KIO-310 could treat Retinitis Pigmentosa, Choroideremia, and Stargardt’s Disease.

United BioSource, LLC Selects Oracle Cloud Safety Technology for its Safety Programs

United BioSource, LLC (UBC), the leading provider of evidence-based research for the biopharma industry, has migrated its safety functions from on-premises to Oracle Argus Cloud Service, a trusted safety case management solution. UBC specializes in generating real-world evidence of product effectiveness, safety, and value that enable emerging and leading pharmaceutical companies to make medicine and specialty therapies safer and more accessible.

Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial

Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study in normal healthy volunteers. CSX-1004 is a human monoclonal antibody infusion that is being developed for the prevention of fentanyl overdose.

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Kiora Pharmaceuticals and the Choroideremia Research Foundation (located in Springfield MA) have partnered to advance a potential new treatment for patients with choroideremia (CHM), a rare, inherited retinal disease that causes blindness. This collaboration will accelerate Kiora's development of a small molecule designed to restore vision in patients with later-stage retinal degeneration. Key Takeaways: Patients with CRM are often initially misdiagnosed with retinitis pigmentosa (RP), as these two conditions have similar symptoms. People with CHM can expect their peripheral vision to get worse over time, leaving only central vision. Eventually, the condition may progress to blindness. There isn't a cure but the partnership between Kiora and CRF could eventually help restore vision. CRF will assist Kiora with access to clinical and scientific thought leaders to assist in further development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration. CRF will also provide aid in enrollment of patients for any future trials of KIO-301.

SYGNATURE DISCOVERY ACCELERATES GLOBAL GROWTH WITH MAJOR NORTH AMERICAN ACQUISITION

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.